(Q36174284)

12 August 2017

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis (English)

1 reference

12 August 2017

0 references

8

Eric Van Cutsem

0 references

John D Hainsworth

6

object named as

John D Hainsworth

1 reference

12 August 2017

Jonathan R Strosberg

1

1 reference

12 August 2017

James C Yao

2

1 reference

12 August 2017

Emilio Bajetta

3

1 reference

12 August 2017

Mounir Aout

4

1 reference

12 August 2017

Bert Bakker

5

1 reference

12 August 2017

Philippe B Ruszniewski

7

1 reference

12 August 2017

Kjell Öberg

9

1 reference

12 August 2017

Marianne E Pavel

10

1 reference

12 August 2017

15 September 2015

1 reference

12 August 2017

Endocrine-Related Cancer

1 reference

12 August 2017

22

1 reference

12 August 2017

6

1 reference

12 August 2017

933-940

1 reference

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4609826

When progressive disease does not mean treatment failure: reconsidering the criteria for progression

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4609826

ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4609826

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4609826

NANETS consensus guidelines for the diagnosis of neuroendocrine tumor

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4609826

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4609826

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4609826

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4609826

RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4609826

Measuring response in solid tumors: unidimensional versus bidimensional measurement

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26373569

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1530/ERC-15-0314

1 reference

12 August 2017

1 reference

12 August 2017

1 reference